Inhibikase Posts $20.5M Q3 Loss, Expands Phase 3 Trial
The pulmonary arterial hypertension developer reported higher research spending as it advanced its global IMPROVE-PAH study.
Updated on Nov. 19, 2026 in Public Companies

Inhibikase Therapeutics reported a third-quarter 2026 net loss of $20.5 million, up from $11.9 million a year earlier, as research and development expenses nearly doubled. The company said its Phase 3 IMPROVE-PAH trial had received regulatory approvals in 28 countries.
Why it matters
The rising loss reflects the cost of advancing a late-stage clinical program for pulmonary arterial hypertension, a condition with limited treatment options. The company's funding position will shape how far and how fast the trial can expand.
The third-quarter net loss was $20.5 million, or $0.10 per share, compared with $11.9 million, or $0.13 per share, a year earlier. Cash, cash equivalents and marketable securities totaled $193.3 million at September 30, 2026, after a $50 million July equity raise.
The players
Inhibikase Therapeutics Inc.
Inhibikase Therapeutics is a publicly traded clinical-stage biopharmaceutical company developing treatments for pulmonary arterial hypertension and related conditions.
The details
Inhibikase said R&D expenses rose to $15 million from $7.6 million, while selling, general and administrative expenses increased to $7.2 million from $5.6 million. For the first nine months of 2026, the net loss totaled $56.4 million, compared with $35.5 million a year earlier. The FDA granted orphan drug designation to its lead candidate IKT-001 in July.
Timeline
July 2026: The company raised $50 million through a sale of 25 million shares to RA Capital Management and received orphan drug designation for IKT-001.
September 30, 2026: Cash and marketable securities totaled $193.3 million at quarter end.
October 2026: Scott M. Wasserman was appointed to the board of directors.
November 2026: The Phase 3 trial had approvals in 28 countries, with 79 of about 180 planned sites activated.
First half of 2027: An interim safety assessment of 50 Part A patients is expected.
Season Trajectory
The expansion of the IMPROVE-PAH trial into 28 countries positions Inhibikase to compete in a pulmonary arterial hypertension market where few newer therapies have reached Phase 3. Its cash position gives it runway through the planned 2027 interim safety readout.
For patients with pulmonary arterial hypertension, the trial's expansion signals a possible future treatment option, though no approval is imminent. Investors should weigh the widening losses against the company's current cash balance and its dependence on further clinical milestones.
The takeaway
Inhibikase's rising losses are the cost of a larger global trial, and the next major signal will be the interim safety data expected in 2027.
What happens next
An interim safety assessment involving 50 patients in Part A is expected during the first half of 2027, and findings from interstitial lung disease-associated pulmonary hypertension research are expected in late 2027 or early 2028.
Further reading
For more on corporate earnings and listed biotech firms, see Public Companies.
Source note: This article includes information reported by MyChesCo.






